Cabozantinib in Hepatocellular Carcinoma: An Interview With Thomas A. Abrams, MD

​Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is a challenging condition to treat, with reported five-year survival rates ranging from 30% to 50%. Recently, the FDA approved cabozantinib (Cabometyx®, Exelixis, Inc.) as second-line treatment for patients with HCC previously treated with sorafenib. Thomas A. Abrams, MD, Assistant Professor of Medicine at Harvard Medical School, spoke with i3 Health about cabozantinib's approval and about the various options now ava...
Continue reading

Metastasis Risk in Postpartum Breast Cancer: An Interview With Virginia Borges, MD, MMSc

​In their previous research, Virginia F. Borges, MD, MMSc, and colleagues identified an increased risk of metastasis for women diagnosed with breast cancer within five years after giving birth. However, in their latest study, Dr. Borges and her fellow researchers from the University of Colorado Cancer Center and Oregon Health & Science University found that the increased risk of metastasis actually lasts for 10 years after the most recent childbirth. In this interview with i3 Health, Dr. Bor...
Continue reading

Using Acupressure to Manage Anxiety, Depression, and Pain in Breast Cancer Survivors: An Interview With Suzanna Zick, ND, MPH

Breast cancer survivors are at an increased risk of developing a myriad of symptoms, including anxiety, depression, pain, and fatigue. Acupressure has been practiced for thousands of years as part of traditional Chinese medicine. In a recent study, Suzanna Zick, ND, MPH, and colleagues have demonstrated that acupressure decreases symptoms of depression, anxiety, pain, and fatigue in breast cancer survivors. In an interview with i3 Health, Dr. Zick spoke about these findings and discussed ways to...
Continue reading

Mark Socinski, MD: First-Line Atezolizumab in Metastatic NSCLC

In an interview with i3 Health, Mark A. Socinski, MD, shares insights regarding the recent FDA approval of atezolizumab (Tecentriq®, Genentech, Inc.) in combination with carboplatin/paclitaxel/bevacizumab for patients with previously untreated metastatic nonsquamous, non-small cell lung cancer (NSCLC) without EGFR or ALK tumor mutations. Dr. Socinski, Executive Medical Director and Medical Oncologist at the Florida Hospital Cancer Institute, was the lead researcher on the IMpower150 trial (NCT02366143), which served as the basis for the FDA approval.

Continue reading

Implementing Molecular Profiling at Initial Diagnosis for Pediatric Brain Tumor Patients With James M. Olson, MD, PhD

James M. Olson, MD, PhD

​Brain and spinal cord tumors are the second most common cancers in children, accounting for 1 out of 4 childhood cancers. Despite intensive treatment, children with histologically diagnosed high-risk medulloblastoma, supratentorial primitive neuroectodermal tumor of the central nervous system (CNS-PNET), and pineoblastoma (PBL) continue to have suboptimal outcomes. James M. Olson, MD, PhD, Professor of Pediatric Hematology/Oncology at University of Washington School of Medicine, and colleagues found that molecular profiling of patients with CNS-PNET/PBL revealed a significant proportion of patients were initially misdiagnosed and consequently overtreated and that other patients have a better prognosis than previously realized. i3 Health spoke with Dr. Olson about these findings and their implications for pediatric brain tumor practice.

Continue reading

© Copyright 2019 i3 Health. All rights reserved.